Latest news with #PTAB
Business Wire
3 days ago
- Business
- Business Wire
Geneoscopy Wins Patent Trial and Appeal Board Decision, Invalidating All 20 Claims of Exact Sciences' '781 Patent
ST. LOUIS, Mo.--(BUSINESS WIRE)-- Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 20 challenged claims of U.S. Patent No. 11,634,781 (the '781 patent) unpatentable. The PTAB's ruling concluded that all claims of the '781 patent are obvious considering prior art related to stool sample collection and processing. The decision to invalidate the '781 patent confirms Geneoscopy's long-held position and clears the path for the continued commercialization of ColoSense. 'The PTAB's final decision validates what we have believed all along—that the claims in the '781 patent should never have been issued,' said Andrew Barnell, CEO and co-founder of Geneoscopy. 'This outcome not only reinforces the strength of our position but helps ensure that invalid patents cannot be used to limit patient access to life-saving colorectal cancer screening options like ColoSense. It's a critical step toward protecting patient choice and advancing high-quality, noninvasive screening solutions.' Geneoscopy filed the IPR petition after Exact Sciences initiated a patent infringement suit in the U.S. District Court for the District of Delaware. The PTAB's ruling bolsters the company's defenses in that case and follows the Board's earlier decision in February to institute review of a second patent asserted by Exact Sciences (U.S. Patent No. 11,970,746) on largely the same grounds on which the '781 patent was just invalidated. In parallel to the pending litigation, Geneoscopy has filed a countersuit alleging breach of contract, misappropriation of trade secrets, false advertising, and unfair competition. About ColoSense ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA) in October 2023. For more information, visit About Geneoscopy, Inc. Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit and follow the company on LinkedIn.
Newsweek
24-06-2025
- Business
- Newsweek
The U.S. Patent Office Should Not Let Itself Be Used for Litigation Gamesmanship
Advocates for ideas and draws conclusions based on the interpretation of facts and data. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Over a decade ago, I co-authored the bipartisan Leahy-Smith America Invents Act to modernize our patent system. One of its key reforms was the creation of a streamlined panel inside the U.S. Patent and Trademark Office (USPTO) called the Patent Trial and Appeal Board (PTAB) to resolve patent disputes more quickly and affordably than drawn-out court battles. Some patent infringers have figured out how to use the PTAB as a backchannel for relitigating resolved disputes, draining American innovators of resources, and giving competitors a second shot after losing in court. The PTAB's recent ruling against Efficient Power Conversion Corporation (EPC), a California-based semiconductor firm, in favor of a Chinese infringer is a prime example. United States Capitol building is pictured. United States Capitol building is pictured. Getty Images EPC holds patented technology for a next-generation power chip, the kind of high-efficiency semiconductor used in electric vehicles, data centers, and aerospace systems. When a Chinese-based competitor named Innoscience began importing products into the United States EPC believed copied its technology, EPC filed a petition with the U.S. International Trade Commission (ITC) asking the U.S. government to block those copycats imports. The ITC responded with a full investigation, including depositions, expert testimony, and a trial before an independent administrative law judge. After months of briefing, the judge ruled that EPC's patent was valid and infringed. When the full bipartisan commission composed of presidentially appointed, Senate-confirmed officials upheld that decision, Innoscience's copycat products were blocked from being imported into the U.S. market. That should have been the end. An innovator company followed the ITC's rigorous, multilayered process, proved its case, and won. Instead, as the ITC was concluding its own investigation, with post-trial briefing underway, the PTAB granted Innoscience's request to institute a brand new review of EPC's patent. Mere weeks after the ITC's order blocking Innoscience's products took effect, the PTAB issued a contradictory decision invalidating key patent claims the ITC had just found valid and infringed. This kind of inconsistent outcome was never what Congress intended when we created the PTAB. The board was meant to resolve disputes efficiently, not reopen cases already settled by another expert agency. And it certainly wasn't meant to undermine the ITC by creating conflicting rulings that foreign infringers can exploit to re-enter the U.S. market. These repeated challenges drain inventors' time and money. Deep-pocketed large corporations—foreign as well as domestic—can wear down smaller firms through sheer volume and cost. Defending just one PTAB challenge can cost patent owners $500,000, and challengers often file multiple challenges against a single patent if they think it poses a competitive threat. Just 10 companies account for nearly a quarter of all PTAB petitions. The consequences are impossible to ignore. An American company that successfully defended its patent in court is still struggling to defend its rights. Meanwhile, a Chinese infringer has been handed another chance to potentially re-enter the U.S. market. In an effort to prevent this kind of overreach, a bipartisan group of lawmakers recently introduced the PREVAIL Act. One of its key provisions could stop duplicative patent challenges by preventing the PTAB from undermining cases already decided by other forums like the ITC. That change would reaffirm that the PTAB exists to streamline justice, not undermine it, and safeguard inventors from facing endless litigation loops after winning in court. I knew when we passed the America Invents Act that we were creating a program with the potential to be used for gamesmanship through repeated litigation and administrative attacks on the validity of a patent. That is why I wrote at the time that the Judiciary Committee I chaired "intend[ed] for the USPTO to address potential abuses and current inefficiencies under its expanded procedural authority." Acting USPTO Director Coke Morgan Stewart could exercise her expanded procedural authority to reverse the PTAB's decision in the EPC case. USPTO policy is that the PTAB should not relitigate cases already nearing resolution in another forum. That safeguard seems to apply here. The ITC had already fully tried and decided this case. Reversing the PTAB's ruling would mark an important step toward restoring accountability within the board and reaffirming that the U.S. patent system exists to protect American innovation. America's patent system should not give deep-pocketed infringers multiple chances in different forums to invalidate patents. The PTAB was created to resolve patent disputes more quickly and at less cost, not encourage infringers. Lamar Smith represented the 21st Congressional District of Texas in the U.S. House from 1987 to 2019 and served as chairman of the Judiciary Committee. The views expressed in this article are the writer's own.
Associated Press
12-06-2025
- Business
- Associated Press
Synthego Prevails In Patent Appeal Confirming Agilent CRISPR Patents Are Invalid
REDWOOD CITY, Calif., June 12, 2025 /PRNewswire/ -- Synthego, a pioneering CRISPR Solutions provider, is pleased to announce that the US Court of Appeals for the Federal Circuit has upheld an earlier ruling invalidating patents held by Agilent Technologies, Inc. See the ruling here. In the original case, ruling dated May 17, 2023, the Patent Trial and Appeal Board (PTAB) ruled in favor of Synthego's petitions seeking to invalidate Agilent's US Patents Nos. 10,337,001 (the '001 patent) and 10,900,034 (the '034 patent) in the Inter Partes Review before the PTAB. The PTAB's original decision invalidated all claims of the Agilent patents, which were directed to guide RNAs having at least one 2'-O-methyl modification ('034 patent) and guide RNAs having certain modifications within 5 nucleotides of their 5' and/or 3' end ('001) patent), as well as methods of using such modified guide RNAs for CRISPR gene editing. 'This critical decision, affirming that Agilent's claims on chemically modified gRNAs are unpatentable, keeps the path clear for broader innovation and advancement in the CRISPR therapeutics market,' said Craig Christianson, CEO of Synthego. 'Synthego will continue our focus on supporting our clients' efforts to enhance human health with curative cell and gene therapies.' Synthego continues to support innovation in the field of CRISPR-enabled research and therapeutics, this affirmation enables researchers and therapeutic developers to continue to drive successful patient outcomes. About Synthego Synthego is a leader in biotechnology, dedicated to delivering best-in-class CRISPR solutions with a mission to accelerate research and development in the pursuit of improved human health. By providing unparalleled access to CRISPR solutions at scale, Synthego enables agility in life science discovery and clinical advancement. With streamlined licensing models and exceptional technical expertise, Synthego empowers researchers and developers to unlock better patient outcomes through innovative CRISPR cell and gene therapies. View original content to download multimedia: SOURCE Synthego
Yahoo
04-06-2025
- Business
- Yahoo
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo
Wells Fargo analyst Mohit Bansal notes that PTAB has instituted Merck's (MRK) patent grant review against Halozyme Therapeutics (HALO) MDASE patents. This patent is one of the patents Merck is fighting against Halozyme. The firm believes this likely reduces the probability of Halozyme prevailing in this case and weakens the bull argument. Wells has an Equal Weight on Halozyme with a price target of $65 on the shares. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HALO: Disclaimer & DisclosureReport an Issue Merck granted review of Halozyme patent claims by PTAB Halozyme's Strategic Positioning and Market Potential Drive Buy Rating Halozyme announces EC approval of Bristol Myers' Opdivo developed with Enhanze Optimistic Buy Rating for Halozyme Amid Price Control Concerns Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley
Yahoo
16-04-2025
- Business
- Yahoo
Sterlington Expands Patent Litigation Practice with Addition of Brent Babcock
NEW YORK, April 16, 2025--(BUSINESS WIRE)--Sterlington PLLC announced today that Brent Babcock has joined the firm as a partner in its Intellectual Property practice. A nationally recognized patent litigator, Babcock brings more than three decades of experience handling high-stakes patent disputes across federal district courts and the U.S. Patent and Trademark Office, with extensive experience in Patent Trial and Appeal Board (PTAB) proceedings. "Brent's arrival meaningfully expands our ability to advise clients in complex patent disputes," said Christopher S. Harrison, managing partner of Sterlington. "His nationally respected PTAB practice and extensive experience in district court litigation, coupled with his technical training and appellate advocacy, make him a valuable asset to our clients and our team." Babcock's practice spans every aspect of patent litigation—from federal district court and PTAB trials to appeals before the U.S. Court of Appeals for the Federal Circuit. He has represented clients in more than 140 proceedings before the PTAB and handled more than 35 patent interferences, as well as numerous reexaminations. His matters have spanned a wide range of technologies, including mechanical systems, semiconductors, medical devices, cellular communications, biotechnology, and software platforms. Although Babcock focuses on patent disputes, he also represents clients in trademark, trade dress, copyright, trade secret, unfair competition, and false advertising matters. "Sterlington offers a rare combination of top-tier talent, a flexible and collaborative team, and a forward-thinking culture that supports sophisticated client work," said Babcock. "The firm's focus on attracting premier lawyers and delivering high-quality results efficiently makes it an ideal home for my national practice." Recognized as PTAB Practitioner of the Year by Managing Intellectual Property in 2022 and consistently ranked among the country's leading patent lawyers by IAM Patent 1000, Babcock is widely regarded as one of the foremost practitioners in post-grant proceedings. His arrival is part of a broader growth trajectory for Sterlington. The firm has added seven lateral partners in as many months. Recent arrivals include Lawrence Waks, a top corporate lawyer and advisor to global brands and celebrity-backed ventures; Robert Ray, a former federal prosecutor who succeeded Kenneth Starr as independent counsel; Jonathan Sherman and Courtney Rockett, highly regarded litigators from Boies Schiller Flexner; and other senior attorneys across the firm's corporate, international arbitration, and private client practices. Babcock joins Sterlington from Loeb & Loeb, where he was chair of the firm's PTAB Trials practice group. Previously, he practiced at Womble Bond Dickinson and Knobbe Martens. He earned his J.D. from Georgetown University Law Center and his M.B.A. from the Georgetown University McDonough School of Business. He holds both bachelor's and master's degrees in mechanical engineering from UCLA. About Sterlington Sterlington PLLC is an international law firm focusing on complex corporate, litigation, and transactional matters. By offering high-level legal expertise and customized client solutions, the firm helps clients around the world achieve their business goals. Visit us at View source version on Contacts Media Inquiries Kate QuinceHead of Marketing and Sign in to access your portfolio
